Recommendation for reporting of disease attributes
| Tier . | AML and patient-specific attributes . |
|---|---|
| Tier 1 | Patient-specific attributes: age, sex, number of lines of prior therapy, prior HSCT(s), bridging therapy received Disease-specific attributes∗: AML subtype, cytogenetic and molecular abnormalities at time of CAR T-cell therapy |
| Tier 2 | Percentage of blasts expressing target antigen |
| Tier 3 | MFI of target antigen or number of molecules/cells of target antigen |
| Tier . | AML and patient-specific attributes . |
|---|---|
| Tier 1 | Patient-specific attributes: age, sex, number of lines of prior therapy, prior HSCT(s), bridging therapy received Disease-specific attributes∗: AML subtype, cytogenetic and molecular abnormalities at time of CAR T-cell therapy |
| Tier 2 | Percentage of blasts expressing target antigen |
| Tier 3 | MFI of target antigen or number of molecules/cells of target antigen |
MFI, mean fluorescent intensity.
Based on internationally accepted criteria.